Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 3, 2014, Pages 357-364

  Tezcan, Okan ^a   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Cancer; Doxorubicin; Gene silencing; MCF 7; MDR; Metastasis; Vimentin

Indexed keywords

DOXORUBICIN; SMALL INTERFERING RNA; VIMENTIN; ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MCF 7 CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; TUMOR INVASION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL MOVEMENT; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; TRANSFECTION; VIMENTIN;

EID: 84899485888     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.01.006     Document Type: Article

References (34)

1. Nurwidya F., Takahashi F., Murakami A., Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012, 44:151-156.
2. Cochard P., Paulin D. Initial expression of neurofilaments and vimentin in the central and peripheral nervous system of the mouse embryo in vivo. J Neurosci 1984, 4:2080-2094.
3. Evans R.M. Vimentin: the conundrum of the intermediate filament gene family. Bioessays 1998, 20:79-86.
4. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
5. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273.
6. Battula V.L., Evans K.W., Hollier B.G., Shi Y., Marini F.C., Ayyanan A., et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 2010, 28:1435-1445.
7. Radisky D.C. Epithelial-mesenchymal transition. J Cell Sci 2005, 118:4325-4326.
8. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
9. Iseri O.D., Kars M.D., Arpaci F., Atalay C., Pak I., Gunduz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 2011, 65:40-45.
10. Eckes B., Colucci-Guyon E., Smola H., Nodder S., Babinet C., Krieg T., et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 2000, 113(Pt 13):2455-2462.
11. Ivaska J., Vuoriluoto K., Huovinen T., Izawa I., Inagaki M., Parker P.J. PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 2005, 24:3834-3845.
12. Kokkinos M.I., Wafai R., Wong M.K., Newgreen D.F., Thompson E.W., Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. Cells Tissues Organs 2007, 185:191-203.
13. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
14. Hendrix M.J., Seftor E.A., Seftor R.E., Trevor K.T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997, 150:483-495.
15. Kars M.D., Iseri O.D., Gunduz U., Ural A.U., Arpaci F., Molnar J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 2006, 26:4559-4568.
16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
17. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637.
18. Jackson A.L., Linsley P.S. Noise amidst the silence: off-target effects of siRNAs?. Trends Genet 2004, 20:521-524.
19. Sommers C.L., Heckford S.E., Skerker J.M., Worland P., Torri J.A., Thompson E.W., et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992, 52:5190-5197.
20. Valque H., Gouyer V., Gottrand F., Desseyn J.L. MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS One 2012, 7:e46699.
21. Vuoriluoto K., Haugen H., Kiviluoto S., Mpindi J.P., Nevo J., Gjerdrum C., et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011, 30:1436-1448.
22. Nijkamp M.M., Span P.N., Hoogsteen I.J., van der Kogel A.J., Kaanders J.H., Bussink J. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol 2011, 99:344-348.
23. Hu L., Lau S.H., Tzang C.H., Wen J.M., Wang W., Xie D., et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004, 23:298-302.
24. Wei J., Xu G., Wu M., Zhang Y., Li Q., Liu P., et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 2008, 28:327-334.
25. McInroy L., Määttä A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 2007, 360:109-114.
26. Paccione R.J., Miyazaki H., Patel V., Waseem A., Gutkind J.S., Zehner Z.E., et al. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther 2008, 7:2894-2903.
27. Pan T.L., Wang P.W., Huang C.C., Yeh C.T., Hu T.H., Yu J.S. Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. J Proteomics 2012, 75:4676-4692.
28. Pan Y., Zhong L.J., Zhou H., Wang X., Chen K., Yang H.P., et al. Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis. Acta Pharmacol Sin 2012, 33:798-808.
29. Iseri O.D., Kars M.D., Arpaci F., Gunduz U. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol 2010, 65:447-455.
30. Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997, 14:2167-2173.
31. Kang J.H., Song K.H., Jeong K.C., Kim S., Choi C., Lee C.H., et al. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 2011, 11:334.
32. Yao L., Zhang Y., Chen K., Hu X., Xu L.X. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One 2011, 6:e24684.
33. Mendez M.G., Kojima S., Goldman R.D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010, 24:1838-1851.
34. De Craene B., van Roy F., Berx G. Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal 2005, 17:535-547.